Intended for healthcare professionals


NICE recommends oral treatment for preventing chronic and episodic migraines

BMJ 2024; 385 doi: (Published 11 April 2024) Cite this as: BMJ 2024;385:q843
  1. Elisabeth Mahase
  1. The BMJ

The National Institute for Health and Care Excellence (NICE) has recommended atogepant for the prevention of chronic and episodic migraines in adults whose previous treatments have failed.1

The final draft guidance says that to be eligible a person must have had at least four migraine days a month and at least three failed previous …

View Full Text

Log in

Log in through your institution


* For online subscription